Loading stock data…
DAIICHI SANKYO COMPANY LIMITED (4568.T)
TSE¥2,597+61.50 (+2.43%)
Market ClosedLast close Jun 29
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Daiichi Sankyo Company, Limited in the Healthcare sector is trading at ¥2,614 with a market capitalization of $4.5T. Wall Street consensus targets ¥4,205 (17 analysts), implying a +60.9% move over the next 12 months. The stock is currently near its 52-week low of ¥2,390, remaining 16.5% below its 200-day moving average. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +60.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (JPY) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | ¥1.04T↓ | ¥1.28T↓ | ¥1.60T↓ | ¥1.89T |
| Gross Profit | ¥691.49B↓ | ¥914.95B↓ | ¥1.19T↓ | ¥1.47T |
| Operating Income | ¥73.03B↓ | ¥120.58B↓ | ¥211.59B↓ | ¥331.93B |
| Net Income | ¥66.97B↓ | ¥109.19B↓ | ¥200.73B↓ | ¥295.76B |
Peer Comparison
JNJUNHPFE
Fundamentals
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or g...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥4.54T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.78
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.15
Div Yield
Strong income play. Yield provides a meaningful total return floor.
402.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.81%
Volume
Today's trading volume
4.47M
Recent News
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
New Drugs Are Replacing Chemo for Aggressive Breast Cancer
Drug companies have found promising new options for one of the most aggressive and hardest-to-treat forms of breast cancer after decades with few breakthroughs. Gilead Sciences won Food and Drug Administration approval Wednesday to sell its drug Trodelvy as a first treatment for newly diagnosed patients with the advanced form of a type of breast cancer known as “triple negative” because it has characteristics that render common treatments ineffective. It is the second such approval in about a month: AstraZeneca and Daiichi Sankyo rival drug, Datroway, was approved for a similar group of patients in May.
A Spanish biotech banks $87M to make differentiated ADCs
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
Assessing Daiichi Sankyo Company (TSE:4568) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot Daiichi Sankyo Company (TSE:4568) has drawn attention after a period of weaker share performance, with the stock down 2.5% over the past day, 6.2% over the past week, and 11.5% over the past 3 months. See our latest analysis for Daiichi Sankyo Company. Recent volatility sits on top of a weaker stretch, with the share price down 28.7% year to date and the 1 year total shareholder return declining 30.17%. This suggests momentum has been fading,...
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.